Article
BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
The Journal of clinical investigation - 15 Nov 2022
Li Kun, Liu Yanan, Ding Yi, Zhang Zhengwei, Feng Juanjuan, Hu Jiaxin, Chen Jiwei, Lian Zhengke, Chen Yiliang, Hu Kewen, Chen Zhi, Cai Zhenyu, Liu Mingyao, Pang Xiufeng
Abstract excerpt
Mutational activation of KRAS is a common oncogenic event in lung cancer, yet effective therapies are still lacking. Here, we identify B cell lymphoma 6 (BCL6) as a lynchpin in KRAS-driven lung cancer. BCL6 expression was increased upon KRAS activation in lung tumor tissue in mice and was positively correlated with the expression of KRAS-GTP, the active form of KRAS, in various human cancer cell lines. Moreover,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.